Development and evaluation of an ethical guideline for decisions to limit life-prolonging treatment in advanced cancer

• Verfasst von: Laryionava, Katsiaryna [VerfasserIn]
• Verfasst von: Mehlis, Katja [VerfasserIn]
• Verfasst von: Winkler, Eva C. [VerfasserIn]
• Titel: Development and evaluation of an ethical guideline for decisions to limit life-prolonging treatment in advanced cancer
• Titelzusatz: protocol for a monocentric mixed-method interventional study
• Verf.angabe: Katsiaryna Laryionava, Katja Mehlis, Elena Bierwirth, Friederike Mumm, Wolfgang Hiddemann, Pia Heußner, Eva C. Winkler
• E-Jahr: 2018
• Jahr: 15.06.18
• Umfang: 9 S.
• Fussnoten: Gesehen am 25.02.2020
• Titel Quelle: Enthalten in: JMIR Research Protocols
• Ort Quelle: Toronto, 2012
• Jahr Quelle: 2018
• Band/Heft Quelle: 7(2018,6) Artikel-Nummer e157, 9 Seiten
• ISSN Quelle: 1929-0748
• DOI: doi:10.2196/resprot.9698
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1690896442

Abstract

Background: Many patients with advanced cancer receive chemotherapy close to death and are referred too late to palliative or hospice care, and therefore die under therapy or in intensive care units. Oncologists still have difficulties in involving patients appropriately in decisions about limiting tumor-specific or life-prolonging treatment. Objective: The aim of this Ethics Policy for Advanced Care Planning and Limiting Treatment Study is to develop an ethical guideline for end-of-life decisions and to evaluate the impact of this guideline on clinical practice regarding the following target goals: reduction of decisional conflicts, improvement of documentation transparency and traceability, reduction of distress of the caregiver team, and better knowledge and consideration of patients’ preferences. Methods: This is a protocol for a pre-post interventional study that analyzes the clinical practice on treatment limitation before and after the guideline implementation. An embedded researcher design with a mixed-method approach encompassing both qualitative and quantitative methods is used. The study consists of three stages: (1) the preinterventional phase, (2) the intervention (development and implementation of the guideline), and 3) the postinterventional phase (evaluation of the guideline’s impact on clinical practice). We evaluate the process of decision-making related to limiting treatment from different perspectives of oncologists, nurses, and patients; comparing them to each other will allow us to develop the guideline based on the interests of all parties. Results: The first preintervention data of the project have already been published, which detailed a qualitative study with oncologists and oncology nurses (n=29), where different approaches to initiation of end-of-life discussions were ethically weighted. A framework for oncologists was elaborated, and the study favored an anticipatory approach of preparing patients for forgoing therapy throughout the course of disease. Another preimplementational study of current decision-making practice (n=567 patients documented) demonstrated that decisions to limit treatment preceded the death of many cancer patients (62/76, 82% of deceased patients). However, such decisions were usually made in the last week of life, which was relatively late. Conclusions: The intervention will be evaluated with respect to the following endpoints: better knowledge and consideration of patients’ treatment wishes; reduction of decisional conflicts; improvement of documentation transparency and traceability; and reduction of the psychological and moral distress of a caregiver team. Registered Report Identifier: RR1-10.2196/9698 [JMIR Res Protoc 2018;7(6):e157]